ABSTRACT
BACKGROUND: Thyroid nodule fine needle aspiration (FNA) biopsies are associated with a low false-negative rate. There is limited data regarding the predictive value of American College of Radiology Thyroid Imaging Reporting and Data System for false-negative FNA. METHODS: This single-center retrospective study evaluated 119 patients who underwent thyroidectomy. The association of TR category, along with other clinical variables, with false-negative FNA was evaluated. RESULTS: The overall false-negative rate of FNA was 10.8% (n = 9). False-negative FNAs were associated with younger age (mean 42 years vs 50.6 years, P = .04), larger nodule size (mean 4.4 cm vs 3.2 cm, P = .03), and a lower TR category (median 3 v 4, P = .01). DISCUSSION: Lower TR category, younger age, and larger nodule size were associated with false-negative FNA of thyroid nodules. These findings should be taken into context when counseling patients with thyroid nodules who have a benign FNA.
Subject(s)
Predictive Value of Tests , Thyroid Neoplasms , Thyroid Nodule , Thyroidectomy , Humans , Biopsy, Fine-Needle , Retrospective Studies , Middle Aged , Thyroid Neoplasms/pathology , Thyroid Neoplasms/diagnostic imaging , Thyroid Neoplasms/surgery , Adult , Female , Male , False Negative Reactions , Thyroid Nodule/pathology , Thyroid Nodule/diagnostic imaging , Thyroid Nodule/surgery , Aged , Radiology Information SystemsABSTRACT
BACKGROUND: There is currently no clear consensus recommendation for the use of short-interval follow-up mammography after a benign-concordant breast biopsy (BCBB), and practice patterns vary widely. The objectives of this study were to evaluate whether a short-interval follow-up mammogram provided clinical utility after stereotactic BCBB and to examine the costs associated with this surveillance strategy. METHODS: A retrospective review of women who underwent a stereotactic breast biopsy yielding benign-concordant results between January 2005 and October 2014 was performed to evaluate findings on subsequent imaging, to calculate compliance with recommended short-interval imaging, and to examine whether subsequent imaging revealed an abnormality at the site of the initial stereotactic BCBB. A cost analysis was performed utilizing Medicare reimbursement rates to calculate projected and actual costs of short-interval follow-up imaging after stereotactic BCBB. RESULTS: Of the 470 stereotactic BCBB performed, a short-interval mammogram was completed in 207 (44.0%), 9 (4.3%) of which had suspicious mammographic findings at the initial biopsy site, and 6 subsequently underwent biopsy, with none resulting in malignant or high-risk pathology. The cost of short-interval mammographic follow-up (nâ¯=â¯207) was calculated at $28,541.16. CONCLUSIONS: This study provides evidence that 6-month follow-up mammography has low clinical utility and unnecessarily increases costs after stereotactic BCBB. A safe and more cost-effective strategy may be resumption of routine mammography at 12 months post-biopsy.
Subject(s)
Breast Neoplasms/pathology , Early Detection of Cancer/statistics & numerical data , Image-Guided Biopsy/statistics & numerical data , Mammography/statistics & numerical data , Adult , Breast Neoplasms/diagnostic imaging , Breast Neoplasms/economics , Breast Neoplasms/surgery , Early Detection of Cancer/economics , Female , Follow-Up Studies , Humans , Image-Guided Biopsy/economics , Mammography/economics , Middle Aged , Neoplasm Staging , Prognosis , Retrospective StudiesSubject(s)
Aneurysm, False , Aorta, Thoracic , Endovascular Procedures/adverse effects , Hemoptysis , Vascular Grafting/adverse effects , Aneurysm, False/diagnosis , Aneurysm, False/etiology , Aneurysm, False/physiopathology , Aorta, Thoracic/diagnostic imaging , Aorta, Thoracic/pathology , Aortic Aneurysm, Thoracic/surgery , Bronchoscopy/methods , Computed Tomography Angiography/methods , Diagnosis, Differential , Endovascular Procedures/methods , Female , Hemoptysis/diagnosis , Hemoptysis/etiology , Humans , Middle Aged , Patient Care Management/methods , Vascular Grafting/methodsABSTRACT
Foregut duplication cysts are extremely rare congenital malformations. Herein we report a case of 73 year old male with a left upper quadrant abdominal lesion identified on CT scan.
Subject(s)
Cysts/diagnostic imaging , Epithelium/diagnostic imaging , Stomach/diagnostic imaging , Aged , Humans , Male , Specimen Handling , Stomach/abnormalities , Tomography, X-Ray ComputedABSTRACT
BACKGROUND: Patients with end-stage renal disease are at increased risk for sudden cardiac death, although the utility of implantable cardioverter-defibrillators (ICDs) in these patients is unknown. OBJECTIVES: The purpose of this study was to evaluate whether end-stage renal disease is an independent risk factor for appropriate ICD therapy for ventricular tachycardia (VT) or ventricular fibrillation (VF) and to compare the long-term survival of ICD recipients with and without end-stage renal disease. METHODS: A retrospective cohort study was performed on ICD recipients at a single center. The primary endpoint was first appropriate ICD therapy for VT/VF. The secondary endpoint was survival. RESULTS: The study included 585 patients, 19 (3.2%) of whom had end-stage renal disease prior to device implantation. Average follow-up time was 2.2 +/- 2.4 years, during which time 156 patients (26.7%) received appropriate ICD therapy. End-stage renal disease was strongly associated with appropriate ICD therapy (hazard ratio 2.30, 95% confidence interval 1.17-4.54) and remained a significant predictor following adjustment for implant indication, ejection fraction, diabetes, hypertension, and beta-blocker use. Survival was significantly shorter in the end-stage renal disease patients, with a median survival time of 3.2 +/- 0.6 (SEM) years in the dialysis cohort and 7.4 +/- 0.5 (SEM) years in those without end-stage renal disease (log rank P = .009). The majority of deaths in the end-stage renal disease cohort were due to non-device-related infection. CONCLUSION: In this cohort, end-stage renal disease was the single greatest predictor of ICD therapies for VT/VF. The survival rate was significantly shorter than that of ICD recipients without end-stage renal disease, suggesting that comorbidities in end-stage renal disease patients meeting current implant indications may reduce the survival benefit of ICD placement in this population.